Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy.
Okuma Y, Ko R, Shukuya T, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Kojima T, Fujita Y, Hino T, Yamanda S, Suzuki T, Fukuizumi A, Sakakibara T, Harada T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Okuma Y, et al. Among authors: imai h. Lung Cancer. 2020 Oct;148:122-128. doi: 10.1016/j.lungcan.2020.08.014. Epub 2020 Aug 20. Lung Cancer. 2020. PMID: 32890794
A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, Yoshii A, Fueki N, Hisada T, Ishizuka T, Saito R, Mori M. Kaira K, et al. Among authors: imai h. Lung Cancer. 2010 Jul;69(1):99-104. doi: 10.1016/j.lungcan.2009.09.012. Epub 2009 Oct 23. Lung Cancer. 2010. PMID: 19853960 Clinical Trial.
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T, Yamamoto N. Akamatsu H, et al. Among authors: imai h. BMC Cancer. 2014 Jan 14;14:18. doi: 10.1186/1471-2407-14-18. BMC Cancer. 2014. PMID: 24422706 Free PMC article.
Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.
Imai H, Shukuya T, Yoshino R, Muraki K, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Tomizawa Y, Takahashi T, Takahashi K, Saito R, Yamamoto N. Imai H, et al. Chemotherapy. 2013;59(4):307-13. doi: 10.1159/000356155. Epub 2014 Jan 24. Chemotherapy. 2013. PMID: 24480845
Multiplexed molecular profiling of lung cancer using pleural effusion.
Akamatsu H, Koh Y, Kenmotsu H, Naito T, Serizawa M, Kimura M, Mori K, Imai H, Ono A, Shukuya T, Taira T, Murakami H, Ohde Y, Endo M, Nakajima T, Takahashi T, Yamamoto N. Akamatsu H, et al. Among authors: imai h. J Thorac Oncol. 2014 Jul;9(7):1048-1052. doi: 10.1097/JTO.0000000000000203. J Thorac Oncol. 2014. PMID: 24926551 Free article.
2,754 results